Quest Diagnostics Incorporated
NYSE:DGX · New York Stock Exchange
-$3.41 today
Vol 0.68M · Avg 0.91M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:DGX · Revenue to Net Income
Key Ratios
Analysis
$11.3B of revenue converted into $1.0B of net income for the selected period. Gross margin is 33.2% and net margin is 9.1%, showing how much revenue survives after costs and taxes. EPS is $9.05, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.0B +11.8% | $9.9B +6.7% | $9.3B -6.4% | $9.9B -8.4% | $10.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $7.5B +13.3% | $6.6B +6.9% | $6.2B -3.9% | $6.5B -2.0% | $6.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.5B +8.6% | $3.2B +5.7% | $3.1B -10.6% | $3.4B -18.4% | $4.2B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 31.9% -0.9pp | 32.9% -0.3pp | 33.2% -1.6pp | 34.7% -4.3pp | 39.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.0B +11.1% | $1.8B +9.6% | $1.6B -13.8% | $1.9B +8.5% | $1.7B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.9B +1.2% | $1.9B +5.0% | $1.8B -9.9% | $2.0B +9.7% | $1.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $570.0M +15.6% | $493.0M +12.3% | $439.0M +0.5% | $437.0M +7.1% | $408.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $2.2B +15.8% | $1.9B +9.4% | $1.7B -4.8% | $1.8B -42.4% | $3.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 19.9% +0.7pp | 19.2% +0.5pp | 18.7% +0.3pp | 18.4% -10.9pp | 29.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.6B +19.1% | $1.3B +6.7% | $1.3B -11.6% | $1.4B -40.0% | $2.4B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 14.5% +0.9pp | 13.6% -0.0pp | 13.6% -0.8pp | 14.4% -7.6pp | 22.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $13.0M -48.0% | $25.0M +127.3% | $11.0M +10.0% | $10.0M +900.0% | $1.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $277.0M +22.6% | $226.0M +38.7% | $163.0M +10.1% | $148.0M -2.6% | $152.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$243.0M -59.9% | -$152.0M -43.4% | -$106.0M +28.9% | -$149.0M -150.3% | $296.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.4B +13.9% | $1.2B +3.3% | $1.2B -9.6% | $1.3B -52.2% | $2.7B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 12.3% +0.2pp | 12.1% -0.4pp | 12.5% -0.4pp | 12.9% -11.9pp | 24.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $314.0M +15.0% | $273.0M +10.1% | $248.0M -6.1% | $264.0M -55.8% | $597.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $992.0M +13.9% | $871.0M +2.0% | $854.0M -9.7% | $946.0M -52.6% | $2.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 9.0% +0.2pp | 8.8% -0.4pp | 9.2% -0.3pp | 9.6% -8.9pp | 18.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $9 +13.7% | $8 +2.8% | $8 -6.5% | $8 -48.9% | $16 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $9 +13.8% | $8 +2.3% | $8 -5.8% | $8 -48.6% | $16 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $111.0M +0.0% | $111.0M -0.9% | $112.0M -3.4% | $116.0M -7.2% | $125.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $113.0M +0.0% | $113.0M +0.0% | $113.0M -4.2% | $118.0M -7.8% | $128.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.53B
Waters Corporation
NYSE:WAT
$23.26B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.18B
United Therapeutics Corporation
NASDAQ:UTHR
$22.75B
Labcorp Holdings Inc.
NYSE:LH
$20.99B
Incyte Corporation
NASDAQ:INCY
$19.66B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.07B
Tenet Healthcare Corporation
NYSE:THC
$14.87B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.16B
ICON Public Limited Company
NASDAQ:ICLR
$11.14B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DGX generate?
Quest Diagnostics Incorporated (DGX) reported $11.04B of revenue in fiscal 2025.
Is DGX profitable?
Quest Diagnostics Incorporated (DGX) reported $992.00M of net income, with a net margin of 9.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.